<DOC>
	<DOCNO>NCT01716104</DOCNO>
	<brief_summary>The purpose study : - To assess safety Afalaza drug within 12 month patient symptoms benign prostatic hyperplasia risk progression . - To assess efficiency Afalaza drug within 12 month patient symptoms benign prostatic hyperplasia risk progression .</brief_summary>
	<brief_title>Clinical Trial Safety Efficiency Afalaza Patients With Symptoms Benign Prostatic Hyperplasia Risk Progression</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1 . Male patient 45 60 y.o . inclusive documented diagnosis Benign prostatic hyperplasia . 2 . Lower urinary tract symptom experience 3 month longer . 3 . Total IPSS score ( International Prostate Symptome Score ) 8 15 . 4 . Prostate volume 30 cm3 . 5 . Maximal urinary flow rate 1015 mL/sec . 6 . Micturition volume 125350 mL . 7 . Residual volume le 100 mL . 8 . Serum PSA level le 4 ng/mL . 9 . Use compliance contraceptive method trial 30 day upon completion participation trial . 10 . Presence patient 's information sheet ( informed consent form ) participation clinical trial . 1 . Invasive therapy BPH include transurethral prostatic resection , thermotherapy , microwave therapy , transurethral needle ablation , stenting , etc . 2 . Malignant oncological disease urogenital system well malignancies localization last 5 year . 3 . Acute urinary retention within 3 month inclusion trial . 4 . Neurogenic dysfunction bladder ear . 5 . Urinary stone disease . 6 . Urethral stricture , bladder neck sclerosis . 7 . History operative aid pelvic organ . 8 . Urogenital infection phase active inflammation . 9 . Systematic administration agent exhibit effect bladder function urine production . 10 . Exacerbation decompensation chronic disease affect possibility patient participate clinical trial , include severe concurrent cardiovascular condition disorder nervous system , renal hepatic insufficiency . 11 . History administration testosterone 5alphareductase inhibitor ( finasteride , dutasteride ) . 12 . History polyvalent allergy . 13 . Allergy/intolerance component drug agent use therapy . 14 . Malabsorption syndrome , include congenital acquire lactase disaccharidase deficiency . 15 . Administration drug specify `` Prohibited concomitant therapy '' , within 3 month enrollment . 16 . Exacerbation decompensation chronic disease affect possibility patient participate clinical trial . 17 . Drug alcohol consumption ( 2 alc . unit daily ) , mental disease . Legal incapacity limit legal capacity . 18 . Legal incapacitation limit legal capacity . 19 . Patients , , investigator 's opinion , fail observe requirement trial adhere study drug administration procedure . 20 . Participation clinical trial within 3 month enrolment trial . 21 . Presence factor , complicate patient 's participation trial ( e.g. , plan lengthy business trip ) . 22 . A patient part center 's research staff , take direct part trial , immediate family member investigator . Immediate family member define spouse , parent , child sibling , regardless whether full blood adopt . 23 . The patient employed Scientific Production Firm Materia Medica Holding LLC , i.e . company 's employee , parttime employee contract , appoint official charge trial , immediate family .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>